Thomson Reuters Q3 Beats, Raises FY2026 Organic Growth Guidance to 8.5-9.0%

What happened

Thomson Reuters reported Q3 2026 results showing 10% total and organic revenue growth, with the Big 3 segments also growing 10% organically, exceeding the FY2026 framework set in early 2026. Management credited strong momentum and raised full-year 2026 total company organic revenue growth guidance to 8.5-9.0% (up from 7.5-8.0%) while maintaining Big 3 segment guidance unchanged. The company completed the sale of a 51% stake in Global Print for ~$500 million on October 1, 2026, and updated total company outlook to exclude that business, with adjusted EBITDA margin expected at ~39%. Capital allocation remained active: $2.0 billion of notes issued in September 2026 and a $600 million share repurchase program completed, on top of the $1.0 billion buyback concluded in February 2026. CEO Steve Hasker highlighted encouraging customer engagement with next-generation CoCounsel Legal and the launch of CoCounsel Tax, Audit & Accounting, but the press release does not provide updated GenAI-enabled ACV penetration or renewal metrics, leaving AI monetization unconfirmed.

Implication

The raised organic growth guidance of 8.5-9.0% reduces near-term downside risk and validates the base case scenario from the DeepValue report (which assumed 7.5-8.0% growth), supporting the potential buy rating. However, the lack of disclosure on GenAI-enabled ACV mix prevents confirmation that AI features are converting into paid expansions, a key thesis breaker identified in the master report. The completed Global Print divestiture is a positive portfolio simplification, but the adjusted EBITDA margin guidance of ~39% for total company (excluding Global Print) appears lower than the ~40.2% implied by previous margin expansion guidance, raising questions about margin erosion in the remaining business. Investors should monitor subsequent earnings calls and disclosures for updated ACV mix, renewal trends, and segment margins, especially in Legal Professionals, to gauge whether the strong organic growth is sustainable without pricing concessions. Until such clarity emerges, the stock may continue trading in a wide range, with the potential for upside if AI attach data improves, but a cautious stance is warranted given the still unresolved competitive threats from agentic AI challengers.

Thesis delta

The Q3 beat and raised FY2026 organic growth guidance from 7.5-8.0% to 8.5-9.0% supports the base case thesis that TRI can sustain mid-to-high single-digit growth despite AI competition. However, the absence of updated GenAI-enabled ACV penetration data means the key monetization trigger remains unconfirmed, preventing a shift to the bull thesis that market narrative will re-rate the stock to $105-$125. Consequently, the thesis shifts from 'test monetization' to 'monetization likely on track but needs explicit confirmation,' reducing downside risk but not yet justifying a higher conviction level.